Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

I-SCREEN

Financiado

Cerrado

I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction...

I(eye)-SCREEN: A real-world AI-based infrastructure for screening and prediction of progression in age-related macular degeneration (AMD) providing accessible shared care The aim of I(eye)-Screen is to develop an artificial intelligence (AI)-based diagnostic decision support system for screening and monitoring of age-related macular degeneration (AMD) at an early stage before vision loss occurs. L... ver más

31/12/2027

MEDIZINISCHE UNIVE...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

MEDIZINISCHE UNIVERSITAET WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-01-01

HORIZON-EIC-2023-PATHFINDEROPEN-01-01: EIC Pathfinder Open Scope:

I+D

Cerrada hace 1 año

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

MEDIZINISCHE UNIVERSITAET WI...

Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

aiVision Innovative AI based Ophthalmologic Diagnosis 71K€ Cerrado

Spectra Spectra A novel diagnostic device to improve retinal imagin... 71K€ Cerrado

DISPOSITIVO ÓPTICO PARA MONITORIZAR LOS OJOS... DISPOSITIVO ÓPTICO PARA MONITORIZAR LOS OJOS Y REALIZAR UNA... Rechazado

RTI2018-095894-B-I00 DESARROLLO DE TECNOLOGIAS INTELIGENTES PARA DIAGNOSTICO DE L... 43K€ Cerrado

iScan Automated retinal scans for early detection of diabetic eye... 71K€ Cerrado

TED2021-131913B-I00 TECNICAS DE DEEP LEARNING E INTERPRETACION DE INTELIGENCIA A... 239K€ Cerrado

Duración del proyecto: 47 meses Fecha Inicio: 2024-01-01
Fecha Fin: 2027-12-31

Líder del proyecto

MEDIZINISCHE UNIVERSITAET WIEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The aim of I(eye)-Screen is to develop an artificial intelligence (AI)-based diagnostic decision support system for screening and monitoring of age-related macular degeneration (AMD) at an early stage before vision loss occurs. Late AMD is the leading cause of legal blindness >50 years with 110 mio individuals at risk. The multidisciplinary consortium brings together a network of clinical retina experts, computer scientists working at the cutting edge of AI development, an infrastructure of community-based opticians/optometrists and an SME experienced in digital platform performance to develop innovative and trustworthy AI tools for broad, real-time AMD screening and monitoring via a cloud-based infrastructure with unlimited access. To achieve the ambitious goal of finding “the needle in the haystack” in early AMD, Optical Coherence Tomography (OCT), a high-resolution, effortless imaging modality is used providing a detailed characterization of the retina in extensive volumetric scans. Breakthrough AI approaches for medical imaging will be developed to enable data-efficient and robust learning from sparse longitudinal OCT data to systematically analyse dense data volumes and identify (sub)clinical markers of disease activity. Clinical sites throughout Europe will collect a longitudinal cohort serving for calibrating and fine-tuning algorithms using the high-end OCT device available at eye clinics. Innovative AI technology will then be created to transfer the detection and monitoring tools to low-cost devices used in next door opticians’/optometrists’ offices. The timing of the project perfectly fits the recent regulatory approval of the first therapy to halt progression of the major atrophic type of AMD. The resulting AI-based “shared care” strategy offers unrestricted accessibility to vision-maintaining care with greatest health equity and provides a role model for screening for systemic, cardiovascular and neurodegenerative disease reflecting retinal biomarkers.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores